Company

Enlivex Therapeutics Ltd.

Headquarters: Ness Ziona, Israel

Employees: 50

TASE: ENLV -3.87%

Market Cap

₪104.9 Million

ILS as of July 1, 2024

US$27.9 Million

Market Cap History

Enlivex Therapeutics Ltd. market capitalization over time

Evolution of Enlivex Therapeutics Ltd. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Enlivex Therapeutics Ltd.

Detailed Description

Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Enlivex Therapeutics Ltd. has the following listings and related stock indices.


Stock: TASE: ENLV wb_incandescent

Stock: NASDAQ: ENLV wb_incandescent

Stock: FSX: 1BT wb_incandescent

Details

Headquarters:

14 Einstein Street

Ness Ziona, 7403618

Israel

Phone: 972 2 670 8072

Fax: 972 2 670 8070